News & Updates
Filter by Specialty:
Saphnelo now available in Malaysia as an add-on treatment for adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)
AstraZeneca’s Saphnelo (anifrolumab) has now become available as add-on treatment for adult patients in Malaysia with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE) following insufficient response to standard therapy, after obtaining regulatory approval earlier this year.
Saphnelo now available in Malaysia as an add-on treatment for adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)
04 Aug 2023
RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy
In the treatment of rheumatoid arthritis (RA), more patients achieve clinical remission with abatacept or certolizumab pegol, but not with tocilizumab, than with active conventional therapy, according to a study.
RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy
17 Jul 2023
Anxiety, depression jeopardize health of axSpA patients
Patients with axial spondyloarthritis (axSpA) may experience a decline in their overall health and functioning due to the presence of comorbid anxiety and depression, as reported in a study from Singapore.
Anxiety, depression jeopardize health of axSpA patients
14 Jul 2023
Real-world data back CV safety of JAK inhibitors
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
